---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273266"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:13:43.027425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agenus reports Q3 net income on MiNK gain; France reimburses BOT/BAL access

## Summary
- France authorizes reimbursed compassionate access for BOT/BAL in refractory MSS mCRC; patients under treatment.
- BOT/BAL shows 42% two-year OS, 20.9-month median OS in 123 heavily pretreated MSS mCRC patients.
- Phase 3 BATTMAN trial initiated Q4 2025 across 100+ sites in Canada, France, Australia, NZ.
- MiNK deconsolidation generates ~$100.9M gain; net income for Q3 and nine-month periods.
- Zydus provides $10M bridge facility ahead of $91M closing; equity at $7.50/share.

## SEC filing metadata
- accession: 0001193125-25-273266
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/0001193125-25-273266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312525273266/agen-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273266
- JSON: https://secwatch.observer/filing/0001193125-25-273266.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.